A study of the transfer of insulin-requiring diabetic patients from U-40 to U-100 Lente insulin.
A pilot study of the transfer of insulin-requiring diabetic patients from U-40 to U-100 Lente insulin was conducted in 16 patients. The patients were returned to U-40 after 12 weeks on U-100. There were no adverse events specifically attributable to the process of transfer. The mean blood glucose values for the last day and the last 2 days on U-100 insulin (154.58 +/- 32.09 mg% and 152.99 +/- 29.23 mg% respectively) were significantly lower than those for the corresponding periods on U-40 insulin (178.06 +/- 38.48 mg% and 169.83 +/- 32.34 mg% respectively), (t = 2.79, p = 0.014 and t = 2.30, p = 0.036 respectively). But there was no significant difference between the mean values for the last but one day on U-40 and U-100 (152.36 +/- 27.81 vs 161.59 +/- 33.82; t = 1.16, p = 0.264). There was no significant increase in frequency (2.3 episodes per week on U40 versus 2.8 episodes per week on U-100) or severity of hypoglycaemic attacks with U-100 insulin. On the basis of this experience we feel that transfer from U-40 to U-100 insulin can be achieved without risk of serious adverse consequences provided the transfer is carried out according to a well-designed plan of action.
Abdulkadir
J
J
Endocrinology-Metabolism Unit, Tikur Anbessa Teaching Hospital, Addis Abeba, Ethiopia.
Mengistu
M
M
Bekele
G
G
D000328:Adult; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005002:Ethiopia; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
D049528:Insulin, Long-Acting